1. Introduction {#sec1-ijms-20-02194}
===============

The development of immunosuppressive drugs is the key to suppressing allograft rejection. In the past two decades, increased immunosuppressive efficiency significantly reduced the incidence of acute rejection. With increased immunosuppression, however, there is also an increased rate of post-transplant infections and malignancies. The risk of cancer after transplantation is increased by three- to five-fold compared with that of the general population, and the prognosis of transplanted patients with malignancy is poorer than that of other cancer patients \[[@B1-ijms-20-02194],[@B2-ijms-20-02194]\]. The high risk of cancer after transplantation has been linked to environmental carcinogenic risk factors, the comorbidities of transplanted recipients, and the detrimental effects of immunosuppressants such as activation of oncogenic viruses, carcinogenic effects of the medications, and loss of immunity for immune-surveillance \[[@B3-ijms-20-02194]\]. The prognosis of recipients diagnosed with cancer is worse than that for cancer patients in the general population; therefore, cancer-related death in post-kidney transplantation is common and requires heightened surveillance \[[@B4-ijms-20-02194]\]. It has been demonstrated that immunosuppressants can influence the efficacy of cancer treatment and lead to poorer tolerated to oncologic treatments \[[@B3-ijms-20-02194]\]. Therefore, interactions between immunosuppressants and cancer therapies should be taken into account when formulating a therapeutic strategy.

Given advancements in cancer therapy, development of immune checkpoint inhibitors employing antibodies targeting programmed cell death 1 (PD-1), PD-1 ligand (PD-L1), or monoclonal antibodies against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) in patients with various types of cancer has steadily increased. However, options for immune checkpoint inhibitors are limited in organ transplant patients because of the high risk of graft rejection and immunosuppression due to chronic use of this treatment ([Figure 1](#ijms-20-02194-f001){ref-type="fig"}). As such, reviewing the efficacy and safety of immune checkpoint inhibitors in organ transplant patients with cancer is necessary. Here, we focus on the efficacy and safety of PD-1 inhibitors in renal transplant patients, given that these drugs may be influenced by different tissue types or immune factors in other organ transplant recipients. Moreover, no data regarding the use of PD-L1 inhibitors, such as atezolizumab, avelumab, or durvalumab, in renal transplant patients are available. Finally, evidence suggests that anti-CTLA4 monoclonal antibodies are associated with a lower risk of rejection in renal transplant recipients compared with anti-PD-1 monoclonal antibodies \[[@B5-ijms-20-02194],[@B6-ijms-20-02194],[@B7-ijms-20-02194]\]. By reviewing the usage of PD-1 inhibitors in renal transplant recipients with advanced cancer, we attempted to provide possible factors that influence the efficacy and safety of these inhibitors.

2. PD-1 Inhibitors in Renal Transplant Patients with Cancer {#sec2-ijms-20-02194}
===========================================================

Tumor cells are known for their ability to inhibit T-cell-mediated immunosurveillance and the effector response by upregulating inhibitory checkpoint molecules, such as the programmed death ligands PD-L1 and PD-L2, which interact with PD-1 on T-cells to suppress their activation \[[@B8-ijms-20-02194]\]. Hence, anti-PD-1 monoclonal antibodies that block PD-1 molecules can promote T-cell activation, consequently stimulating the cell-mediated and humoral anti-tumor response. PD-1 inhibitors such as nivolumab and pembrolizumab have been approved to treat metastatic melanoma, metastatic non-small cell lung cancer, renal cell carcinoma, classical Hodgkin's lymphoma, head and neck squamous cell carcinoma (SCC), urothelial carcinoma, hepatoma previously treated with sorafenib, and metastatic gastric or gastroesophageal junction adenocarcinoma \[[@B9-ijms-20-02194]\]. Renal transplant recipients are at higher risk of developing skin cancers \[[@B10-ijms-20-02194]\], urologic malignancies \[[@B11-ijms-20-02194]\], and other malignancies than the general population \[[@B12-ijms-20-02194]\]. Therefore, knowledge of the anti-tumor effects of PD-1 inhibitors is undoubtedly necessary for renal transplant patients with the aforementioned cancers. Unfortunately, activation of T-cells by PD-1 inhibitors is not specifically against malignant cells; activated T-cells also attack donor alloantigens in transplanted kidneys. In addition, the PD-1/PD-L1 axis is critical to inducing and maintaining the peripheral allograft tolerance in transplant recipients. For example, this axis is involved in the induction of regulatory T-cells (Tregs), which play an important role in suppressing T-cell activation after exposure to alloantigens in renal transplant recipients \[[@B13-ijms-20-02194]\]. Thus, activated-T cells against donor-alloantigen in the transplanted kidney, or the attenuated function of Tregs via blocking the PD-1, can result in graft rejection. However, not all renal transplant patients developed graft rejection after receiving PD-1 inhibitors. Allograft characteristics may be one of the pivotal influential factors. For example, PD-L1 has been identified to protect against alloreactive T-cell-mediated injury in renal tubular epithelial cells. Increased levels of PD-L1 on the graft kidneys possibly promote the host T-cell suppression by preventing the activation of alloreactive T-cells and stimulating apoptosis \[[@B14-ijms-20-02194]\]. Therefore, high levels of PD-L1 in donor tissue can prevent pathologic alloreactivity and graft failure \[[@B15-ijms-20-02194]\]. Aside from the allograft, other factors can affect graft survival after PD-1 inhibitor treatment. Considering these issues, developing an optimal means to maximize the therapeutic effects and minimize the toxicity of PD-1 inhibitors is an important endeavor.

3. Graft Failure After Administration of a PD-1 Inhibitor in Renal Transplant Patients with Advanced Cancer {#sec3-ijms-20-02194}
===========================================================================================================

Our data on the efficacy and safety of PD-1 inhibitors in kidney-transplanted patients with advanced malignancies mainly include case studies ([Table 1](#ijms-20-02194-t001){ref-type="table"} and [Table 2](#ijms-20-02194-t002){ref-type="table"}), owing to the current lack of randomized control trials and the fact that kidney-transplanted patients are consistently excluded in clinical trials of immune checkpoint inhibitors. According to the available data summarized in [Table 1](#ijms-20-02194-t001){ref-type="table"}, 11 renal transplant patients with advanced cancer were reported to have graft failure after anti-PD-1 treatment. The occurrence of graft failure is mainly caused by acute rejection; however, 4 out of 11 renal transplant patients had graft failure after PD-1 inhibitor treatment without tissue evidence \[[@B16-ijms-20-02194],[@B17-ijms-20-02194],[@B18-ijms-20-02194],[@B19-ijms-20-02194]\]. Acute rejection of transplanted kidney after PD-1 inhibitors occurs mainly through T-cell mediated rejection \[[@B20-ijms-20-02194],[@B21-ijms-20-02194],[@B22-ijms-20-02194],[@B23-ijms-20-02194],[@B24-ijms-20-02194],[@B25-ijms-20-02194]\], although antibody-related rejection \[[@B21-ijms-20-02194],[@B22-ijms-20-02194]\] or vascular rejection \[[@B26-ijms-20-02194]\] has also been reported. The occurrence of acute T-cell-mediated rejection after administration of PD-1 inhibitors may be understood from the viewpoint that the activation of T-cells against donor allograft antigens leads to graft failure via T-cell infiltration of the renal interstitium, renal tubular epithelia, and endothelia. This finding is not surprising because acute interstitial nephritis with infiltration of T-cells and granulocytes in renal tissue after treatment with immune checkpoint inhibitors for malignancies has been reported in non-transplanted patients \[[@B27-ijms-20-02194],[@B28-ijms-20-02194]\]. Acute antibody-mediated rejection may be attributed to the proliferative response of B-cells induced by activated T-cells or activation of memory B-cells expressing PD-1 induced by the concomitant reduction in immunosuppressant use during PD-1 inhibitor treatment \[[@B21-ijms-20-02194]\]. Vascular rejection is mainly caused by cell-mediated rejection; however, antibody-mediated rejection or vascular isolated lesions can contribute to vascular rejection \[[@B29-ijms-20-02194]\]. Graft failure in renal transplant patients usually appears after the first dose of a PD-1 inhibitor which causing a severe graft rejection. However, three renal transplant patients with acute rejection appeared after the second, third, or ninth administration. \[[@B22-ijms-20-02194],[@B24-ijms-20-02194],[@B25-ijms-20-02194]\]. After graft failure, almost all kidneys did not regain function, even after treatment with a high-dose steroid, and patients require hemodialysis for rescue \[[@B16-ijms-20-02194],[@B17-ijms-20-02194],[@B20-ijms-20-02194],[@B21-ijms-20-02194],[@B22-ijms-20-02194],[@B23-ijms-20-02194]\]. Nevertheless, a 64-year-old man with advanced Non-small cell lung cancer (NSCLC) developed graft failure after the ninth cycle of nivolumab, but he did not require hemodialysis for rescue because his graft function improved after high-dose administration of a steroid and increased dosage of mycophenolate mofetil (MMF) and tacrolimus \[[@B24-ijms-20-02194]\].

With regard to immunosuppressive regimens before the initiation of a PD-1 inhibitor, five of 11 renal transplant patients with graft failure received only prednisolone monotherapy \[[@B16-ijms-20-02194],[@B20-ijms-20-02194],[@B21-ijms-20-02194],[@B23-ijms-20-02194],[@B26-ijms-20-02194]\]. Two patients had decreased dosage of immunosuppressive medications \[[@B22-ijms-20-02194],[@B24-ijms-20-02194]\]. In one patient, the dosage of immunosuppressive medications was decreased, and tacrolimus was switched to everolimus \[[@B25-ijms-20-02194]\]. In one patient, tacrolimus and MMF were replaced with azathioprine and everolimus \[[@B17-ijms-20-02194]\]. One patient had no immunosuppressive medication \[[@B18-ijms-20-02194]\], and another patient had no information on the titration of immunosuppressive medications \[[@B19-ijms-20-02194]\]. Unsurprisingly, lowering the dose of immunosuppressants before a PD-1 inhibitor significantly increases the risk of graft failure because immunosuppressive therapies are vital in regulating acute allograft rejection and inducing long-term transplanted kidney survival \[[@B30-ijms-20-02194]\].

In terms of the efficacy of PD-1 inhibitors in renal transplant patients with graft failure and advanced cancer, 5 out of the 11 reported patients experienced tumor progression, 4 had a partial response, 1 had a complete response, and 1 had no tumor response data. In three patients with graft failure and advanced cutaneous squamous cell carcinoma (cSCC), all patients exhibited partial and complete response after PD-1 inhibitor treatment. For the renal transplant patient with a complete response of advanced cSCC, he received a combined anti-PD-1 and anti-CTLA4 immunotherapy. However, the patient had sudden cardiac death with unclear etiology during dialysis.

4. Intact Graft and No Tumor Progression After a PD-1 Inhibitor in Renal Transplant Patients with Advanced Cancer {#sec4-ijms-20-02194}
=================================================================================================================

Intriguingly, not all renal transplant patients with advanced malignancy experience graft failure after treatment of PD-1 inhibitors. Thus, these cases without graft failure are discussed in this section to provide possible explanations ([Table 1](#ijms-20-02194-t001){ref-type="table"}). First, a 77-year-old male kidney transplant recipient maintained his graft function after three doses of anti-CTLA-4 antibodies of ipilimumab at a dose of 3 mg/kg every 3 weeks followed by the anti-PD-1 antibody of nivolumab at a dose of 3 mg/kg every 2 weeks for metastatic melanoma. In contrast with other patients with graft failure after ipilimumab followed by PD-1 inhibitors \[[@B20-ijms-20-02194],[@B21-ijms-20-02194]\], this patient maintained an immunosuppressive regimen with 5 mg of prednisolone daily and 5 mg of tacrolimus twice daily before nivolumab \[[@B31-ijms-20-02194]\]. Clinically, the patient's metastatic melanoma even progressed after nivolumab. Hence, whether the continuation of immunosuppressants reduces the anti-tumor response of PD-1 inhibitors should be further investigated.

In a second case, a 70-year-old male kidney transplant recipient was treated with nivolumab at a dose of 3 mg/kg every 2 weeks for metastatic duodenal adenocarcinoma after poor response to standard chemotherapy. Immunosuppressive regimens included concurrent prednisolone and the mammalian target of rapamycin (mTOR) inhibitors with sirolimus. Prednisolone was titrated as follows: 40 mg daily 1 week before nivolumab, 20 mg daily after nivolumab, 10 mg daily between 2 weeks and 6 months after nivolumab, and, finally, 5 mg daily. Tacrolimus was replaced by sirolimus before anti-PD-1, and serum sirolimus levels were initially maintained at 4--6 ng/mL after anti-PD-1 and then increased to 10--12 ng/mL 2 weeks after. The patient maintained his graft function without tumor progression \[[@B32-ijms-20-02194]\].

In the third case, a 68-year-old woman with a living-related kidney transplant developed metastatic cSCC. Nivolumab was administrated owing to tumor progression even after radiotherapy, chemotherapy, and targeted therapy. Immunosuppressive regimens included 5 mg of prednisolone daily and sirolimus before initiation of nivolumab. Her tacrolimus was switched early to sirolimus before radiotherapy. The patient's graft function was well maintained, and no evidence of tumor progression was found after 11 cycles of nivolumab \[[@B36-ijms-20-02194]\]. Calcineurin inhibitor (CNI) minimization or elimination is a critical strategy to decrease CNI toxicities, such as nephrotoxicity, the worsening risk of cardiovascular disease, new-onset diabetes, increased incidence of neoplasms, and viral infections. Some studies have demonstrated well-maintained graft functions without increased rates of graft rejection and failure after CNI elimination using sirolimus in kidney transplantation \[[@B37-ijms-20-02194],[@B38-ijms-20-02194]\]. In addition, the mTOR signaling pathway plays a vital role in tumor initiation and progression. Treatment with mTOR inhibitors can reduce high mTOR signaling levels in various cancer types \[[@B39-ijms-20-02194]\]. Recent studies also suggest that early conversion to an mTOR inhibitor-based maintenance regimen can reduce cSCC \[[@B40-ijms-20-02194],[@B41-ijms-20-02194]\]. Treatment with mTOR inhibitors and concomitant immune checkpoint inhibitors could maintain T-cell energy \[[@B42-ijms-20-02194]\], and mTOR inhibitors have been demonstrated to stimulate naïve T-cell differentiation into Tregs, especially in the presence of IL-2 \[[@B33-ijms-20-02194]\]. The antitumor effect and immunologic tolerance of mTOR inhibitors in renal transplant patients after PD-1 inhibitors must be further investigated.

In the fourth case, we previously reported a 61-year-old woman who had undergone deceased donor transplantation and eventually advanced urothelial carcinoma. Anti-PD-1 monoclonal antibody (pembrolizumab; 1 mg/kg), humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab, 4 mg/kg), and chemotherapy with cisplatin (50 mg/m^2^) and gemcitabine (500 mg/m^2^) were administered intravenously every 3 weeks for 11 cycles. We maintained immunosuppressive regimens, including a fixed dose of mycophenolate mofetil (1 g/day) and 9--10 g/day tacrolimus, to maintain serum tacrolimus levels between 5 and 10 ng/mL before the first dose of pembrolizumab. The patient's graft function remained stable, and serial images demonstrated significant tumor regression \[[@B43-ijms-20-02194]\]. Platinum-based drugs may enhance the anti-tumor effects of immunotherapy by eliminating immunosuppressive cells, such as Tregs; anti-angiogenic agents may also improve endogenous immune antitumor responses by normalizing the tumor neovasculature \[[@B44-ijms-20-02194]\]. Additionally, acute renal allograft rejection was identified to be associated with increased levels of serum or urine VEGF \[[@B45-ijms-20-02194],[@B46-ijms-20-02194]\]. VEGF inhibitors may prevent graft rejection \[[@B47-ijms-20-02194],[@B48-ijms-20-02194]\], and are currently applied to prevent rejection after corneal transplantation \[[@B34-ijms-20-02194],[@B49-ijms-20-02194]\]. Nevertheless, the humanized anti-VEGF monoclonal antibody should still be investigated in future research in efforts to prevent rejection of transplanted kidney in humans.

According to Tio et al. \[[@B19-ijms-20-02194]\], 4 out of 5 male renal transplant patients with advanced melanoma had intact graft after PD-1 inhibitor treatment. A low rejection rate of renal allograft was observed in this study group after PD-1 inhibitor treatment. These four patients with intact graft were all treated with a PD-1 inhibitor (pembrolizumab), and one of them was treated initially with pembrolizumab followed by an anti-CTLA4 monoclonal antibody with ipilimumab. With regard to the use of immunosuppressive medications, these four patients had immunosuppressive medications before treatment with the PD-1 inhibitor. However, the authors did not mention whether immunosuppressive regimens were continued without titration before the initiation of PD-1 inhibitor treatment. Moreover, concurrent administration of immunosuppressive regimens, including prednisolone, MMF, and mTOR inhibitor (everolimus), was used in only one renal transplant recipient. Whether the initiation of CNI elimination was due to the use of mTOR inhibitor is not clear. Therefore, reviewing the regimen and dosage of immunosuppressive medications before and after PD-1 inhibitor treatment in these four renal transplant patients and exploring why these patients with advanced melanoma were able to maintain graft function after PD-1 inhibitor treatment are necessary. Regarding the outcome of advanced melanoma after pembrolizumab, three out of four renal transplant recipients with intact graft had disease progression, and one had a partial response.

Winkler et al. \[[@B35-ijms-20-02194]\] safely administered anti-PD-1 antibodies to two renal transplant patients with advanced melanoma. One patient was a 60-year-old female renal transplant patient with advanced melanoma treated with four cycles of nivolumab. Her renal function was well maintained after PD-1 inhibitor treatment. Her immunosuppressive regimens included prednisolone and MMF before the PD-1 inhibitor treatment. Cyclosporine was stopped after she was diagnosed with metastatic disease. The other patient was a 55-year-old male renal transplant patient with advanced uveal melanoma treated with four doses of pembrolizumab. His graft function remained stable with mild proteinuria after PD-1 inhibitor treatment. His immunosuppressive medications with cyclosporine and prednisolone were discontinued after diagnosis of uveal melanoma 2 years before anti-PD-1 treatment. The immunosuppressive regimens in the male patient with advanced uveal melanoma remained unchanged after initiation of anti-PD-1 treatment, but the other patient stopped cyclosporine. Nevertheless, the tumors in these two patients progressed even after PD-1 inhibitor treatment.

In another report by Zehou et al. \[[@B50-ijms-20-02194]\], a 74-year-old male renal transplant patient with advanced melanoma was treated with three cycles of ipilimumab followed by nivolumab at 3 mg/kg, combined with radiotherapy, every 2 weeks. His renal functions initially deteriorated, owing to *Escherichia coli* sepsis, but improved after treatment. The patient remained on immunosuppressants with 5 mg of prednisone, azathioprine, and everolimus before the administration of PD-1 inhibitor. No graft rejection was found. The immunosuppressive regimen of the patient remained unchanged. However, the advanced melanoma continued to deteriorate, and the patient ultimately died 1 year later.

Collectively, the tumor in four out of the 11 renal transplant patients with intact graft responded well to a PD-1 inhibitor. The types of tumor were advanced duodenal adenocarcinoma, advanced cSCC, advanced urothelial carcinoma, and advanced melanoma. Advanced melanoma progressed even after PD-1 inhibitor treatment in seven other renal transplant patients with intact graft. In the report by Tio et al., five out of seven renal transplant patients with intact grafts continued immunosuppressant therapy without titration, and three had immunosuppressive medications, including an mTOR inhibitor.

5. Kidney Transplant Patients after PD-1 Inhibitors {#sec5-ijms-20-02194}
===================================================

Among the 22 renal transplant patients after PD-1 inhibitor treatment, 14 patients developed melanoma (13 cutaneous and one uveal), four developed cutaneous cSCC, two developed NSCLC, one developed a duodenal adenocarcinoma, and one developed urothelial carcinoma. For advanced melanoma in renal transplant patients, the disease control rate with a PD-1 inhibitor was 21%. The disease control rate in renal transplant patients with advanced cSCC was 100%. The patients with duodenal adenocarcinoma and urothelial carcinoma both had a partial response with a PD-1 inhibitor. Eleven out of 22 renal transplant patients (50%) experienced rejection after PD-1 inhibitor treatment. In terms of drug choice of PD-1 inhibitors on renal transplant patients with advanced cancer, 13 patients were administrated with nivolumab and nine patients were administrated with pembrolizumab. 8 out of 13 (61.5%) renal transplant patients with advanced cancer treated with nivolumab had graft failure, whereas 3 out of 9 (33%) renal transplant patients with advanced cancer treated with pembrolizumab had graft failure. Disease control rate in renal transplant patients with advanced cancer administrated by nivolumab and pembrolizumab is 50% and 33 %, respectively. It is difficult to draw conclusions that nivolumab had higher rejection and response rate than pembrolizumab in renal transplant population owing to lack of controlled trial and only a few available cases studies.

6. Conclusions {#sec6-ijms-20-02194}
==============

In our review of published cases, PD-1 inhibitors showed anti-tumor effects on advanced malignancies, including metastatic melanoma, cSCC, urothelial tumors, and duodenal adenocarcinoma in renal transplant patients. Interestingly, a high response rate of cSCC and a low response rate of advanced melanoma after PD-1 inhibitor treatment were noted in renal transplant patients. Moreover, PD-1 inhibitors showed a high risk of severe graft rejection without regaining renal function even after treatment with high-dose steroids. Almost all affected renal transplant patients required hemodialysis for rescue. These patients received low-dose or reduced immunosuppressive medications before the initiation of PD-1 inhibitor treatment. By contrast, most renal transplant patients with intact graft continued to take immunosuppressive medications or combined treatment with mTOR inhibitor. For patients who benefited from anti-tumor treatment with anti-PD-1 inhibitors without rejection, two renal transplant recipients were possibly due to the use of low-dose steroid and an mTOR inhibitor, one patient's advanced urothelial carcinoma regressed after combined treatment with anti-PD-1, anti-VEGF, and chemotherapy without immunosuppressant titration, and one patient had no information in the published article. mTOR inhibitor and anti-VEGF medication may be a key feature for regulating immune tolerance after the administration of PD-1 inhibitors in renal transplant patients. On the basis of these case studies, drawing conclusions regarding the ideal combination of drugs that facilitate anti-PD-1 treatment to achieve the optimal therapeutic effects, and to maintain graft tolerance in renal transplant patients, is difficult. Hence, further studies in renal transplant patients after PD-1 inhibitor treatment are warranted to establish the best treatment strategy and explore an ideal predictive biomarker.
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![The role of T-cell suppression and immune checkpoint blockage in tumor and organ rejection. Activation of a T cell via 3-signal pathway by an antigen presenting cell (APC) is illustrated. The donor cells are rejected when the T cells are activated. Therefore, the immunosuppressants, which inhibit CD3 (Anti-CD3 mAB), calcineurin (Cyclosporine or Tacrolimus), CD80/86 (CTLA4-Ig), IL-2 signaling (Anti-CD25 mAB), JAK3 (JAK3 inhibitor), mammalian target of rapamycin (mTOR) (Sirolimus or Everolimus), and those interfere with the proliferative phase in the cell cycle (MPA, mycophenolate mofetil (MMF), azathioprine, and Fk778; not illustrated) are the key to successful post-transplantation outcomes. On the other hand, the employment of immune checkpoint inhibitors in transplant patients with cancer may increase the tumor killing while giving the chance for graft rejection. Therefore, fine-tuning the immunosuppressants and immune checkpoint inhibitors in transplanted patients with cancer is vital in achieving graft tolerance while treating cancer. APC, antigen presenting cell; CTLA4, cytotoxic T-lymphocyte-associated protein 4; IL-2, interleukin-2; IL-15, interleukin-15; JAK3, Janus kinase 3; PI3K, phosphoinositide 3-kinase; TCR, T-cell receptor; MHC I, major histocompatibility complex; mTOR, mammalian target of rapamycin; PD1, programmed cell death 1; PDL 1/2, programmed death-ligand 1/3.](ijms-20-02194-g001){#ijms-20-02194-f001}

ijms-20-02194-t001_Table 1

###### 

Clinical response and graft rejection after PD-1 inhibitors in various advanced malignancies of renal transplant patients.

  Authors                                    Year   Types of Advanced Malignancy   Age   Sex   Transplant to Malignancy/CPI (Years)   PD-1 Inhibitors               Concurrent Anti-Cancer Treatment   Immuno-Suppressants           Graft Integrity   Biopsy                                         Time till Graft Rejection             Rescue                   Cancer Outcome
  ------------------------------------------ ------ ------------------------------ ----- ----- -------------------------------------- ----------------------------- ---------------------------------- ----------------------------- ----------------- ---------------------------------------------- ------------------------------------- ------------------------ ----------------
  Spain et al. \[[@B19-ijms-20-02194]\]      2016   Melanoma                       48    M     12/14                                  Ipilimumab // nivolumab       Monotherapy                        Prednisolone                  Rejected          Acute cellular rejection                       8 days after 1st nivolumab            HD                       PD
  Alhamad et al. \[[@B20-ijms-20-02194]\]    2016   Melanoma                       68    M     5/6                                    Ipilimumab // pembrolizumab   Monotherapy                        Prednisolone                  Rejected          Acute cellular & antibody-mediated rejection   3 weeks after 1st pembrolizumab       HD                       PD
  Boils et al. \[[@B21-ijms-20-02194]\]      2016   NSCLC                          74    M     5/15                                   Nivolumab                     Monotherapy                        Prednisolone & cyclosporine   Rejected          Acute cellular & antibody-mediated rejection   3rd nivolumab                         HD                       No info.
  Lipson et al. \[[@B22-ijms-20-02194]\]     2016   cSCC                           57    F     5/8                                    Pembrolizumab                 Monotherapy                        Prednisolone                  Rejected          Acute & chronic cellular rejection             2 months after 1st pembrolizumab      HD                       PR
  Ong et al. \[[@B15-ijms-20-02194]\]        2016   Melanoma                       63    F     3/UK                                   Nivolumab                     Monotherapy                        Prednisolone                  Rejected          None                                           1 week after 1st nivolumab            HD                       PR
  Tamain et al. \[[@B23-ijms-20-02194]\]     2016   NSCLC                          64    M     25/UK                                  Nivolumab                     Monotherapy                        Tacrolimus & MMF              Rejected          Acute cellular rejection                       9th nivolumab cycle                   Immuno-suppressants \*   PD
  Kwatra et al. \[[@B16-ijms-20-02194]\]     2017   Melanoma                       58    M     11/11                                  Pembrolizumab                 Monotherapy                        Azathioprine & everolimus     Rejected          None                                           2nd pembrolizumab                     Hospice                  PD
  Miller et al. \[[@B17-ijms-20-02194]\]     2017   cSCC                           68    M     6/7                                    Nivolumab & ipilimumab        Combined                           None                          Rejected          None                                           8 days after 1st dual immunotherapy   HD                       CR
  Deltombe et al. \[[@B24-ijms-20-02194]\]   2017   Melanoma                       60    F     11/13                                  Nivolumab                     Monotherapy                        Everolimus                    Rejected          Acute cellular rejection                       25 days after 2nd nivolumab           HD                       PD
  Goldman et al. \[[@B25-ijms-20-02194]\]    2018   cSCC                           50    M     13/13                                  Nivolumab                     Monotherapy                        Prednisolone                  Rejected          Acute & chronic vascular rejection             13 days after 1st nivolumab           HD                       PR
  Tio et al. \[[@B18-ijms-20-02194]\]        2018   Melanoma                       48    M     0.5/4                                  Nivolumab                     Monotherapy                        Prednisone & tacrolimus       Rejected          None                                           1st nivolumab                         HD                       PR

Note: NSCLC, non-small cell lung cancer; cSCC, cutaneous squamous cell carcinoma; UK, unknown; NS, not specified; CPI, checkpoint inhibitor; //, followed by, MMF, mycophenolate mofetil; HD, hemodialysis; PD, progressive disease; PR, partial response; CR, complete response; \*, renal function improved after methylprednisolone administration and increased dose of MMF and tacrolimus.

ijms-20-02194-t002_Table 2

###### 

Clinical response and intact graft after PD-1 inhibitors in various advanced malignancies of renal transplant patients.

  Authors                                   Year   Types of Advanced Malignancy   Age   Sex   Transplant to Malignancy/CPI (Years)   PD-1 Inhibitors               Concurrent Anti-Cancer Treatment       Immuno-Suppressants              Graft Integrity   Biopsy   Time till Graft Rejection   Rescue   Cancer Outcome
  ----------------------------------------- ------ ------------------------------ ----- ----- -------------------------------------- ----------------------------- -------------------------------------- -------------------------------- ----------------- -------- --------------------------- -------- ----------------
  Herz et al. \[[@B30-ijms-20-02194]\]      2016   Melanoma                       77    M     1/8                                    Ipilimumab // nivolumab       Monotherapy                            Prednisone & tacrolimus          Intact            N/A      N/A                         N/A      PD
  Barnett et al. \[[@B31-ijms-20-02194]\]   2017   Duodenal adenocarcinoma        70    M     5/6                                    Nivolumab                     Monotherapy                            Prednisone & sirolimus           Intact            N/A      N/A                         N/A      PR
  Kittai et al. \[[@B32-ijms-20-02194]\]    2017   cSCC                           69    F     4/15                                   Nivolumab                     Monotherapy                            Prednisone & sirolimus           Intact            N/A      N/A                         N/A      SD
  Wu et al. \[[@B33-ijms-20-02194]\]        2017   UC                             61    F     5/8                                    Pembrolizumab                 Bevacizumab, cisplatin & gemcitabine   MMF & tarcolimus                 Intact            N/A      N/A                         N/A      PR
  Tio et al. \[[@B18-ijms-20-02194]\]       2018   Melanoma                       65    M     NS                                     Pembrolizumab // ipilimumab   Monotherapy                            Prednisone, MMF & everolimus     Intact            N/A      N/A                         N/A      PD
  Tio et al. \[[@B18-ijms-20-02194]\]       2018   Melanoma                       70    M     NS                                     Pembrolizumab                 Monotherapy                            Prednisone & tacrolimus          Intact            N/A      N/A                         N/A      PD
  Tio et al. \[[@B18-ijms-20-02194]\]       2018   Melanoma                       75    M     NS                                     Pembrolizumab                 Monotherapy                            Prednisone                       Intact            N/A      N/A                         N/A      PR
  Tio et al. \[[@B18-ijms-20-02194]\]       2018   Melanoma                       65    M     NS                                     Pembrolizumab                 Monotherapy                            Prednisone, MMF & tarcolimus     Intact            N/A      N/A                         N/A      PD
  Winkler et al. \[[@B34-ijms-20-02194]\]   2018   Melanoma                       60    F     11/13                                  Nivolumab                     Monotherapy                            Prednisolone & MMF               Intact            N/A      N/A                         N/A      PD
  Winkler et al. \[[@B34-ijms-20-02194]\]   2018   Melanoma (uveal)               58    M     21/23                                  Pembrolizumab                 Montoherapy                            Cyclosporine                     Intact            N/A      N/A                         N/A      PD
  Zehou et al. \[[@B35-ijms-20-02194]\]     2018   Melanoma                       74    M     0.5/4                                  Ipilimumab // nivolizumab     Monotherapy                            Prednisolone, MMF & everolimus   Intact            N/A      N/A                         N/A      PD

Note: cSCC, cutaneous squamous cell carcinoma; UC, urothelial carcinoma; CPI, checkpoint inhibitor; NS, not specified; //, followed by; MMF, mycophenolate mofetil; N/A, not available; PD, progressive disease; PR, partial response; SD, stable disease.
